Kedmi, Ranit

CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy

Rosenblum, D., Gutkin, A., Kedmi, R., Ramishetti, S., Veiga, N., Jacobi, A. M., Schubert, M. S., Friedmann-Morvinski, D., Cohen, Z. R., Behlke, M. A., et al. (2020) · Science Advances

RNA Interference and Gene DeliveryCRISPR and Genetic Engineering

Cited by 614

The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation

Kedmi, R., Ben-Arie, N., & Peer, D. (2010) · Biomaterials

RNA Interference and Gene DeliveryNanoparticle-Based Drug Delivery

Cited by 546

A modular platform for targeted RNAi therapeutics

Kedmi, R., Veiga, N., Ramishetti, S., Goldsmith, M., Rosenblum, D., Dammes, N., Hazan-Halevy, I., Nahary, L., Leviatan-Ben-Arye, S., Harlev, M., et al. (2018) · Nature Nanotechnology

RNA Interference and Gene DeliveryNanoparticle-Based Drug Delivery

Cited by 320

Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes

Veiga, N., Goldsmith, M., Granot, Y., Rosenblum, D., Dammes, N., Kedmi, R., Ramishetti, S., & Peer, D. (2018) · Nature Communications

RNA Interference and Gene DeliveryNanoparticle-Based Drug Delivery

Cited by 308